<DOC>
	<DOC>NCT02112942</DOC>
	<brief_summary>A multi-part study to evaluate the safety and PK of single ascending doses of IDX21549 in healthy and HCV-infected subjects. The effect of food on the PK of IDX21549 will also be evaluated. Antiviral activity will also be assessed in HCV-infected subjects.</brief_summary>
	<brief_title>Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>All subjects Subjects are in good general health. Subjects have provided written informed consent form. All subjects of childbearing potential must have agreed to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug. HCV Subjects Documented clinical history compatible with chronic hepatitis C without cirrhosis. Treatmentna√Øve HCV Genotype 1 All subjects Pregnant or breastfeeding Coinfected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV). Decompensated liver disease Other clinically significant medical conditions or laboratory abnormalities.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>HCV</keyword>
</DOC>